Bank of America Corp DE Has $932,000 Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Bank of America Corp DE boosted its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 108.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 110,050 shares of the specialty pharmaceutical company's stock after buying an additional 57,356 shares during the quarter. Bank of America Corp DE owned about 0.22% of KalVista Pharmaceuticals worth $932,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Ameriprise Financial Inc. acquired a new position in KalVista Pharmaceuticals during the fourth quarter worth $452,000. Algert Global LLC acquired a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at about $88,000. Allostery Investments LP acquired a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at about $4,058,000. Boxer Capital Management LLC acquired a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at about $13,467,000. Finally, PDT Partners LLC grew its position in shares of KalVista Pharmaceuticals by 56.8% in the fourth quarter. PDT Partners LLC now owns 35,201 shares of the specialty pharmaceutical company's stock valued at $298,000 after purchasing an additional 12,747 shares during the last quarter.

KalVista Pharmaceuticals Stock Performance

NASDAQ KALV opened at $14.36 on Friday. The firm has a 50-day simple moving average of $12.07 and a 200 day simple moving average of $10.61. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $15.50. The stock has a market cap of $713.92 million, a PE ratio of -3.95 and a beta of -0.01.

Insider Transactions at KalVista Pharmaceuticals

In other news, major shareholder Venrock Healthcare Capital Par acquired 25,000 shares of the company's stock in a transaction dated Wednesday, April 9th. The stock was bought at an average price of $9.42 per share, with a total value of $235,500.00. Following the completion of the acquisition, the insider now owns 5,303,985 shares in the company, valued at approximately $49,963,538.70. This represents a 0.47% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Paul K. Audhya sold 2,776 shares of the firm's stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $11.84, for a total transaction of $32,867.84. Following the sale, the insider now directly owns 106,611 shares of the company's stock, valued at approximately $1,262,274.24. The trade was a 2.54% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 8,730 shares of company stock valued at $102,226. Corporate insiders own 10.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on KALV. Jones Trading reaffirmed a "buy" rating and issued a $30.00 price target on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, KalVista Pharmaceuticals has an average rating of "Buy" and an average price target of $24.83.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

Want to see what other hedge funds are holding KALV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.